0A88 Stock Overview
A life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
10x Genomics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.73 |
| 52 Week High | US$39.06 |
| 52 Week Low | US$9.32 |
| Beta | 1.93 |
| 1 Month Change | -8.17% |
| 3 Month Change | -24.24% |
| 1 Year Change | -70.86% |
| 3 Year Change | -83.77% |
| 5 Year Change | n/a |
| Change since IPO | -93.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A88 | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | -3.9% | 1.2% | -1.5% |
| 1Y | -70.9% | -31.5% | 7.2% |
Return vs Industry: 0A88 underperformed the UK Life Sciences industry which returned -32.7% over the past year.
Return vs Market: 0A88 underperformed the UK Market which returned 6.8% over the past year.
Price Volatility
| 0A88 volatility | |
|---|---|
| 0A88 Average Weekly Movement | 9.1% |
| Life Sciences Industry Average Movement | 7.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.1% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0A88's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0A88's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 1,306 | Serge Saxonov | www.10xgenomics.com |
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; Visium platform includes Spatial Gene Expression, HD Spatial Gene Expression, and Spatial Gene and Protein Expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides; and Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions.
10x Genomics, Inc. Fundamentals Summary
| 0A88 fundamental statistics | |
|---|---|
| Market cap | US$1.33b |
| Earnings (TTM) | -US$182.63m |
| Revenue (TTM) | US$610.79m |
2.0x
P/S Ratio-6.6x
P/E RatioIs 0A88 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A88 income statement (TTM) | |
|---|---|
| Revenue | US$610.79m |
| Cost of Revenue | US$196.00m |
| Gross Profit | US$414.78m |
| Other Expenses | US$597.41m |
| Earnings | -US$182.63m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.49 |
| Gross Margin | 67.91% |
| Net Profit Margin | -29.90% |
| Debt/Equity Ratio | 0% |
How did 0A88 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/13 04:22 |
| End of Day Share Price | 2025/03/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
10x Genomics, Inc. is covered by 20 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |
| Kyle Mikson | Canaccord Genuity |